Table of Contents
The South African Pharmaceutical industry : The pharmaceutical industry, a vital one which incorporates research and development, manufacture, import, distribution, wholesale and retail of pharmaceutical products, was valued at R39.3bn in 2015. The original drugs sub-sector remains important, contributing 48.2% of industry sales value but the generics sub-sector is the fastest-growing. The recently established state-owned pharmaceutical company, Ketlaphela will start manufacturing antiretroviral drugs in 2019, thus challenging the sales of imported generics to a country that has the world’s largest government-funded antiretroviral programme.
A changing Sector: Although pharmaceutical companies acknowledge that their primary responsibility is to ensure access to affordable healthcare for all consumers, some stakeholders believe companies continue to place large profits before improved health. There has been increased lobbying for reform of the patent system to support the availability of cheaper generic drugs and the reduction in price of originals. With the Intellectual Property policy currently under review and the private healthcare sector the subject of a Competition Commission enquiry, the South African pharmaceutical industry is likely to undergo change.
The report on the Pharmaceutical industry describes merger and acquisition activity, the latest regulatory developments and discusses factors influencing the success of the sector. The report profiles 90 companies ranging from South Africa’s two largest pharmaceutical manufacturers, Aspen Pharmacare and Adcock Ingram to newcomers to the Top 20, Mylan and Valeant Pharmaceuticals which both have less than 2% share of the market. Also profiled are African Medicines (Pty) Ltd t/a Pakmed Self Medication and GNLD International (Pty) Ltd, companies that use the services of contract manufacturers such as Wrapsa. Large national retailers with in-house pharmacies like Clicks and Pick ‘n Pay, which have proved to be fierce competition to traditional independent and community pharmacies, are also profiled in this report.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...